Horama SA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Horama SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11069
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Horama SA (Horama) is a biotechnology company, which develops gene therapy products based on recombinant adeno-associated virus (rAAV) vectors for the treatment of rare ophthalmic diseases, including retinopathies and maculopathies. Its pipeline gene replacement products include HORA-RPE65, developed for the treatment of retinal dystrophy caused by RPE65 gene mutations; HORA-PDE6B, is designed for the treatment of retinitis pigmentosa (RP) caused by PDE6ß defects; HORA-RLBP1, being developed for the treatment of retinal dystrophy caused by RLBP1 mutations. The company has clinical and academic collaborations with Institute for Neurosciences of Montpellier, Reference Centers for rare ophthalmological diseases, among others. Horama is headquartered in Paris, lle-de-France, France.

Horama SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Horama SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Horama SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Horama SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Horama SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Horama SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Horama SA, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Horama Raises Additional USD4.1 Million in Series B Financing 10
Horama Raises USD22 Million in Series B Financing 12
Private Equity 14
Horama Raises USD4.4 Million in Private Equity Financing 14
Equity Offering 15
Horama Raises USD0.6 Million in Private Placement of Shares 15
Horama Spin off from Inserm Transfert 16
Horama SA – Key Competitors 17
Horama SA – Key Employees 18
Horama SA – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Corporate Communications 20
May 15, 2018: HORAMA Names Dr Russell Greig As New Board Chairman 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Horama SA, Pharmaceuticals & Healthcare, Key Facts 2
Horama SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Horama SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Horama SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Horama SA, Deals By Therapy Area, 2012 to YTD 2018 8
Horama SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Horama Raises Additional USD4.1 Million in Series B Financing 10
Horama Raises USD22 Million in Series B Financing 12
Horama Raises USD4.4 Million in Private Equity Financing 14
Horama Raises USD0.6 Million in Private Placement of Shares 15
Horama Spin off from Inserm Transfert 16
Horama SA, Key Competitors 17
Horama SA, Key Employees 18

List of Figures
Horama SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Horama SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Horama SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Horama SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Horama SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Horama SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Horama SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Horama SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Horama SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Krung Thai Bank PCL:企業の戦略・SWOT・財務分析
    Krung Thai Bank PCL - Strategy, SWOT and Corporate Finance Report Summary Krung Thai Bank PCL - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Fluor Corporation:企業の戦略・SWOT・財務情報
    Fluor Corporation - Strategy, SWOT and Corporate Finance Report Summary Fluor Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Westwater Resources, Inc.:企業のM&A・事業提携・投資動向
    Westwater Resources, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Westwater Resources, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • Intersect ENT Inc (XENT):企業の財務・戦略的SWOT分析
    Summary Intersect ENT Inc (Intersect), formerly Sinexus Inc is a medical device company that offers chronic sinusitis solutions. The company offers steroid releasing implants and mini steroid implants. It provides surgical solutions for patients, disease recurrence with recurrent symptoms. Intersect …
  • Deciphera Pharmaceuticals LLC (DCPH):製薬・医療:M&Aディール及び事業提携情報
    Summary Deciphera Pharmaceuticals LLC (Deciphera Pharmaceuticals) is a research and development company that develops, designs, and commercializes kinase inhibiting drugs. The company provides clinical pipeline of kinase inhibitors such as tumor-targeted therapies and immuno-targeted therapies. It u …
  • Smrt Corporation Ltd.:企業の戦略・SWOT・財務分析
    Smrt Corporation Ltd. - Strategy, SWOT and Corporate Finance Report Summary Smrt Corporation Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Gulfport Energy Corp (GPOR):企業の財務・戦略的SWOT分析
    Gulfport Energy Corp (GPOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Nanomerics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Nanomerics Ltd (Nanomerics) is a healthcare solution provider that develops drug delivery solutions for poorly water soluble drugs, nucleic acids and peptides. The company offers products such as METDoloron, METSporine, METAmphizon, METEnkalon, MET undisclosed, MET ocular undiscl, ocular und …
  • BankNordik P/F:企業の戦略・SWOT・財務分析
    BankNordik P/F - Strategy, SWOT and Corporate Finance Report Summary BankNordik P/F - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Natural Capsules Ltd (524654):企業の財務・戦略的SWOT分析
    Natural Capsules Ltd (524654) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Polymedco Inc:医療機器:M&Aディール及び事業提携情報
    Summary Polymedco Inc (Polymedco) is a medical device company that manufactures and markets laboratory instruments, reagents and kits. The company offers FIT testing, ESR testing, chemistry testing instruments, oc-auto fit, oc-lights fit, oc-auto sensor, diana, oc-automicro 80, epi procolon, sediten …
  • Franklin Covey Co. (FC):企業の財務・戦略的SWOT分析
    Franklin Covey Co. (FC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • AGR Holdings AS:企業の戦略的SWOT分析
    AGR Holdings AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • RespireRx Pharmaceuticals Inc (RSPI):企業の財務・戦略的SWOT分析
    RespireRx Pharmaceuticals Inc (RSPI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Verisante Technology Inc (VRS)-医療機器分野:企業M&A・提携分析
    Summary Verisante Technology Inc (Verisante), develops and commercializes products for the early detection of all forms of skin cancer. The company’s key product offerings include Verisante Aura, Verisante Core and Verisante MSI Camera. The Verisante Aura is used for skin cancer detection, and Veris …
  • Karachaganak Petroleum Operating BV:企業の戦略的SWOT分析
    Karachaganak Petroleum Operating BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Redx Pharma Plc (REDX):企業の財務・戦略的SWOT分析
    Summary Redx Pharma Plc (Redx Pharma), formerly Redx Pharma Ltd is a drug discovery and development company that develops early stage and small molecule therapeutics. The company’s pipeline products include inhibitors for oncology and anti-infectives for treatment of diseases that include influenza …
  • Florida State University:製薬・医療:M&Aディール及び事業提携情報
    Summary Florida State University (FSU) is an educational service provider that offers graduation and research services. The university offers graduate, undergraduate, professional degree and master degree programs. It offers educational programs in areas of applied studies, arts and sciences, busine …
  • Murree Brewery Co. Ltd.:企業の戦略・SWOT・財務分析
    Murree Brewery Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Murree Brewery Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Lannett Co Inc (LCI):企業の財務・戦略的SWOT分析
    Lannett Co Inc (LCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆